← Human Trials & Peer-Reviewed Studies
Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial
Plain-language guide to PMID 33203625 (2020): randomized and single-blind clinical study study of Carnosine in 158 patients.
Key Facts
- PMID
- 33203625
- Journal
- BMJ open
- Year
- 2020
- Study type
- Clinical Study
- Authors
- Wu D et al. (12 authors)
- DOI
- 10.1136/bmjopen-2020-037182
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Carnosine, published as a clinical study.
The 16S ribosomal RNA (16S rRNA) next-generation sequencing (NGS) is used to evaluate the effect of two different therapies on the distribution of the gastrointestinal microbiota.
Why It Was Studied
Helicobacter pylori (H. pylori) is the most well-known risk factor for gastric cancer.
At present, H. pylori shows varying levels of resistance to different treatments, leading to a lower rate of H. pylori eradication.
Who Took Part
The abstract describes 158 patients taking part.
PubMed tags the participants as women only.
Patients are randomised (1:1) to the two groups for a 14-day therapy.
How the Study Was Run
The researchers set it up as a randomized and single-blind study.
The patients were allocated by chance, so the Carnosine group and the comparison group should start out alike.
Only one side, usually the patients, was kept unaware of whether Carnosine was given.
A time span of 14 days appears in the methods.
The primary outcome is the rate of H. pylori eradication.
Secondary outcomes are the incidence of adverse events and the gastrointestinal microbiota distribution.
What Was Measured
At present, H. pylori shows varying levels of resistance to different treatments, leading to a lower rate of H. pylori eradication.
Topics PubMed links to this paper include Amoxicillin, Anti-Bacterial Agents, Anti-Ulcer Agents, Carnosine, China, Helicobacter Infections and Helicobacter pylori.
The authors tagged it with the keywords gastroenterology, gastrointestinal infections and microbiology.
What This Means in Plain Language
The paper is a randomized and single-blind study of Carnosine in 158 patients over 14 days.
The publication is from 2020 (BMJ open), a journal based in England.
More context: the Carnosine compound page, all human trials.
Our Notes on the Compound
Carnosine: A dipeptide of beta-alanine and histidine found in muscle and brain; studied as a supplement in human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.